This new funding will be used primarily to accelerate US commercial adoption of DEXTER, its soft tissue robotic surgery system, as well as to support ongoing clinical and product development initiatives. A major focus of the US expansion continues to be the Ambulatory Surgery Center (ASC) market—one of the fastest-growing segments in surgical care, driven by the ongoing shift toward efficient, outpatient surgery.
"This funding marks another important milestone on our journey," said Greg Roche, CEO of Distalmotion. "The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for DEXTER. The ongoing support from our investors reaffirms our roadmap, our mission, and the value DEXTER brings to minimally invasive surgery."
In conjunction with the financing, Distalmotion has named Chas McKhann as Executive Chairman of the Board of Directors. With more than 25 years in the MedTech and life sciences industries, Mr. McKhann brings a wealth of experience in scaling medical device companies, commercial acceleration, and guiding organizations through strategic growth. Mr. McKhann previously served ...
